Clinical trials: CINV
CINV
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
- Trial name
- NCT01857232
- Testing
- Ondansetron, Dexamethasone, Fosaprepitant
- Where
- Denmark
- Volunteers
- 342 people
- Sponsor
- Acacia Pharma Ltd
Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
The primary objective is to evaluate the efficacy of two different doses of IV palonosetron in the prevention of chemotherapy induced nausea and vomiting in MEC and HEC patients through 120 hours after start of chemotherapy in…
- Trial name
- NCT01442376
- Testing
- Palonosetron, Ondansetron
- Where
- 67 sites in United States, Argentina and 14 more
- Volunteers
- 502 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving MEC.
- Trial name
- NCT01500226
- Testing
- Rolapitant, Granisetron, Dexamethasone
- Where
- United States
- Volunteers
- 1,369 people
- Sponsor
- Tesaro, Inc.
Emesis, Vomiting
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
Olanzapine-containing regimens for CINV prophylaxis may provide even better protection than aprepitant-containing regimens.
- Conditions
- Emesis, Vomiting, Nausea Post Chemotherapy, Nausea
- Trial name
- OlaCINV (NCT03478605)
- Testing
- Olanzapine, Aprepitant Pill, Ondansetron
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment.
- Trial name
- Aroma-CINV (NCT07209501)
- Testing
- Aromatherapy inhaler
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
At present, the clinical studies of 5-HT3RA are aimed at nausea and vomiting induced by single-day chemotherapy, but there are many chemotherapy schemes that require multi-day administration in clinical practice.
- Trial name
- NCT04472143
- Testing
- Granisetron Transdermal Delivery System
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Chemotherapy-induced Nausea and Vomiting
Granisetron Transdermal Patch System for Prevention of CINV by CapeOX
This study aims to explore the prevention of delayed chemotherapy induced by CAPOX regimen with granisetron transdermal patch。
- Trial name
- NCT05325190
- Testing
- Granisetron Transdermal Patch System
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control…
- Trial name
- NCT01594749
- Testing
- Fosaprepitant dimeglumine, Dexamethasone, Ondansetron
- Volunteers
- 1,015 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-Induced Nausea and Vomiting, Lung Cancer
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT02445872
- Testing
- Aprepitant, Palonosetron, Dexamethasone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang University
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Trial name
- NCT01596400
- Testing
- granisetron transdermal system, Granisetron IV
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
This study is testing whether acupuncture at a point on the wrist called "Neiguan" can help reduce nausea and vomiting in patients undergoing stem cell transplantation.
- Trial name
- NCT07747194
- Testing
- Acupuncture, Conventional care
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiao Wang
Multiple Myeloma, Autologous Stem Cell Transplantation
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy.
- Trial name
- FONDO-LOW (NCT06588413)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Augusta University
Liver Cancer, Liver Metastasis
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM).
- Trial name
- NCT00430313
- Testing
- Electro-Stimulation of Yongquan (K1) Acupoint
- Sponsor
- M.D. Anderson Cancer Center